Pre-Test Novel Targeted Therapies for Relapsed/Refractory Multiple Myeloma Pre-Test Which of the following factors are associated with nonadherence in relapsed/refractory multiple myeloma? Adverse effects and perceived inefficacy Comorbidities and low socioeconomic status Older age and polypharmacy Physician communication and costs Unsure In the MajesTEC-1 clinical trial, which of the following agents was shown to have an ORR of 63% in patients with 4 or more lines of therapy? Ciltacabtagene autoleucel Idecabtagene vicleucel Selinexor Teclistamab Unsure Which of the following are the most common grade 3-4 adverse events associated with selinexor treatment for relapsed/refractory multiple myeloma? Anemia, keratopathy, and pneumonia Cardiomyopathy, acute kidney injury, and thrombocytopenia Thrombocytopenia, anemia, and hyponatremia Venous thrombotic events, fatigue, and pneumonia Unsure Please rate your ability to distinguish among newer therapeutic options for the management of multiple myeloma. Excellent Very Good Good Fair Poor
